Abstract:Background Current non-invasive methods of assessing disease activity in systemic lupus erythematosus (SLE) are of limited sensitivity and specificity. Testing includes acute phase markers, autoantibodies and complement levels. Although measurements of dsDNA antibodies and complement C3/C4 levels are routine, they remain of limited value. Improved blood and urine markers may help in early detection of flare, distinction between flare and chronic damage, and monitoring response to therapy. Methods A total of 87 patients with SLE were tested for the following cytokines in serum and urine: monocyte chemoattractant protein 1 (MCP-1), regulated upon activation, normal T cell expressed and secreted (RANTES), soluble tumour necrosis factor receptor 1 (sTNF-R1), interferon-inducible protein 10 (IP-10), monocyte inhibitory protein 1α (MIP-1α) and vascular endothelial growth factor (VEGF). Patients attending the Lupus Unit at St Thomas’ Hospital, London, UK were divided into active lupus nephritis (LN), inactive LN and non-renal SLE groups based on their renal pathology and SLE disease activity index (SLEDAI). Cytokine testing was performed using the FIDIS multiplex bead assay. Results The mean level of serum sTNF-R1 was higher in the active LN group compared with both inactive LN and non-renal SLE groups ( p < 0.001). For urine measurements there were significant differences between active LN and non-renal SLE for VEGF ( p = 0.016), after statistical correction for multiple testing. Both urinary and serum sTNF-R1 and IP-10 levels correlated with SLEDAI scores ( p < 0.001), while serum VEGF correlated weakly with SLEDAI ( p = 0.025). The optimum combination for differentiating active from inactive LN patients was serum VEGF, sTNF-R1, MCP-1 and glomerular filtration rate plus urinary sTNF-R1 and protein-creatinine ratio. Conclusion These results indicate that for active LN, sTNF-R1 could be a useful serum cytokine marker, with potential for VEGF in the urine. This study has confirmed the ability of the multiplex bead technique to detect cytokines in a good analytical range, including very low and high levels, in both serum and urine. Combining serum and urine markers provided additional sensitivity in distinguishing active from inactive LN.

The Potential Role of Neutrophil Reactivity Intensity and Reactive Lymphocytes as Extended Hematological Parameters to Detect Active Systemic Lupus Erythematosus

Peripheral CD24hi CD27+ CD19+ B Cells Subset As a Potential Biomarker in Naïve Systemic Lupus Erythematosus.

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

[The Clinical Significance of Hematological Damage in Systemic Lupus Erythematosus and Related Antibodies].

A potential biomarker of disease activity in systemic lupus erythematosus, systemic immune-inflammation index

Neutrophil-to-C3 Ratio and Neutrophil-to-lymphocyte Ratio Were Associated with Disease Activity in Patients with Systemic Lupus Erythematosus

Potential biomarkers for diagnosis and assessment of disease activity in systemic lupus erythematosus

Correlation of hematological parameters, antibodies and cytokines with disease activity in systemic lupus erythematosus: a cross-sectional study

The Expression of Peripherial Blood Neutrophil CD64 in Systemic Lupus Erythematosus with Infection or Disease Activation

Assessment of hematologic indices for diagnosis in juvenile systemic lupus erythematosus

A systematic review and meta-analysis of the diagnostic accuracy of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in systemic lupus erythematosus

CD56brightCD16-to CD57+CD56dimCD16+NK Cell Ratio Discriminates Disease Activity and Renal Involvement in Patients with Systemic Lupus Erythematosus

PD-L1-expressing neutrophils as a novel indicator to assess disease activity and severity of systemic lupus erythematosus

The Relationship between Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio to Degree of Activity in Systemic Lupus Erythematosus

Using AFR+PNI Model for Predicting Disease Activity in Patients With Systemic Lupus Erythematosus

The Relationship of Neutrophil Lymphocyte Ratio and Levels of Vitamin D against Disease Activity Systemic Lupus Erythematosus

Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients

Role of Neutrophil Extracellular Traps Regarding Patients at Risk of Increased Disease Activity and Cardiovascular Comorbidity in Systemic Lupus Erythematosus

Evaluation of disease activity in systemic lupus erythematosus using standard deviation of lymphocyte volume combined with red blood cell count and lymphocyte percentage

Elevation of Metrnand Its Association with Disease Activity in Systemic Lupus Erythematosus

Soluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritis